Business
Precigen to Announce Fourth Quarter and Full Year 2020 Financial Results on March 1st
- Management will also present at the H.C. Wainwright Virtual Global Life Sciences Conference; webcast available March 9th - GERMANTOWN, Md., Feb. 22, 2021
About this update from Precigen, Inc.
[{"type":"text","content":"- Management will also present at the H.C. Wainwright Virtual Global Life Sciences Conference; webcast available March 9th -\n\n\nGERMANTOWN, Md., Feb. 22, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release fourth quarter and full year 2020 financial results after the market closes on Monday, March 1, 2021. The Company will host a conference call that day at 4:30 PM ET to discuss financial results and provide a general business update.\n\n \n \n \n \n \n \n\n \nThe conference call may be accessed by dialing 1-888-317-6003 (Domestic US), 1-866-284-3684 (Canada) or 1-412-317-6061 (International) and providing the number 9387943 to join the Precigen Conference Call. Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call.\nHelen Sabzevari, PhD, President and CEO, will also present at the H.C. Wainwright Virtual Global Life Sciences Conference and the on-demand webcast will be available starting Tuesday, March 9, 2021 at 7:00 AM ET. \nParticipants may register and access the webcasts for both events through Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.\nPrecigen: Advancing Medicine with Precision™Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on Twitter @Precigen and LinkedIn.\nCautionary Statement Regarding Forward-Looking Statements Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectation...